Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies

Paul Davies, Kelly M. Hinkle, Nour N. Sukar, Bryan Sepulveda, Roxana Mesias, Geidy Serrano, Dario R. Alessi, Thomas G. Beach, Deanna L. Benson, Charles L. White, Rita M. Cowell, Sonal S. Das, Andrew B. West, Heather L. Melros

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Missense mutations in LRRK2 (leucine-rich repeat kinase 2) are a major cause of PD (Parkinson's disease). Several antibodies against LRRK2 have been developed, but results using these polyclonal antibodies have varied widely leading to conflicting conclusions. To address this challenge, the Michael J. Fox Foundation for Parkinson's Research generated a number of monoclonal antibodies targeting epitopes across the LRRK2 protein. In the present paper, we report optimized protocols and results for ten monoclonal antibodies for immunoblotting, immunohistochemistry, immunoprecipitation and kinase activity assays, in rat, mouse and human brain tissue. Several efficacious antibodies were identified, but results demonstrate that the mouse monoclonal N241A/34 is suitable for most applications, with the best overall rabbit monoclonal antibody being c41-2. These antibodies produced a dominant band of the expected size via immunoblotting and a lack of labelling in tissue derived from LRRK2-knockout animals under optimized conditions. A significant proportion of LRRK2 protein localizes to insoluble fractions and no evidence of truncated LRRK2 protein was detected in any fraction from rodent or human tissues. An assay was developed for the robust detection of LRRK2 kinase activity directly from frozen mouse and human brain tissue, but precipitous declines in activity were observed that corresponded to increasing post-mortem intervals and processing times. Finally, we demonstrate the highest levels of brain-localized LRRK2 in the striatum, but note differential expression patterns between rat and mouse in both striatum and cortex. Anti-LRRK2 monoclonal antibodies that are unlimited in availability together with the proposed standardized protocols should aid in the definition of LRRK2 function in both health and disease.

Original languageEnglish (US)
Pages (from-to)101-113
Number of pages13
JournalBiochemical Journal
Volume453
Issue number1
DOIs
StatePublished - Jul 1 2013

Fingerprint

Leucine
Phosphotransferases
Monoclonal Antibodies
Protein Kinases
Tissue
Antibodies
Brain
Immunoblotting
Rats
Assays
Missense Mutation
Proteins
Immunoprecipitation
Parkinson Disease
Epitopes
Rodentia
Labeling
Immunohistochemistry
Rabbits
Animals

Keywords

  • Immunohistochemistry
  • Kinase assay
  • Leucine-rich repeat kinase 2 (LRRK2)
  • Parkinson's disease

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Davies, P., Hinkle, K. M., Sukar, N. N., Sepulveda, B., Mesias, R., Serrano, G., ... Melros, H. L. (2013). Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. Biochemical Journal, 453(1), 101-113. https://doi.org/10.1042/BJ20121742

Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. / Davies, Paul; Hinkle, Kelly M.; Sukar, Nour N.; Sepulveda, Bryan; Mesias, Roxana; Serrano, Geidy; Alessi, Dario R.; Beach, Thomas G.; Benson, Deanna L.; White, Charles L.; Cowell, Rita M.; Das, Sonal S.; West, Andrew B.; Melros, Heather L.

In: Biochemical Journal, Vol. 453, No. 1, 01.07.2013, p. 101-113.

Research output: Contribution to journalArticle

Davies, P, Hinkle, KM, Sukar, NN, Sepulveda, B, Mesias, R, Serrano, G, Alessi, DR, Beach, TG, Benson, DL, White, CL, Cowell, RM, Das, SS, West, AB & Melros, HL 2013, 'Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies', Biochemical Journal, vol. 453, no. 1, pp. 101-113. https://doi.org/10.1042/BJ20121742
Davies, Paul ; Hinkle, Kelly M. ; Sukar, Nour N. ; Sepulveda, Bryan ; Mesias, Roxana ; Serrano, Geidy ; Alessi, Dario R. ; Beach, Thomas G. ; Benson, Deanna L. ; White, Charles L. ; Cowell, Rita M. ; Das, Sonal S. ; West, Andrew B. ; Melros, Heather L. / Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. In: Biochemical Journal. 2013 ; Vol. 453, No. 1. pp. 101-113.
@article{bbda5889409f4a899652ae74554e55ca,
title = "Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies",
abstract = "Missense mutations in LRRK2 (leucine-rich repeat kinase 2) are a major cause of PD (Parkinson's disease). Several antibodies against LRRK2 have been developed, but results using these polyclonal antibodies have varied widely leading to conflicting conclusions. To address this challenge, the Michael J. Fox Foundation for Parkinson's Research generated a number of monoclonal antibodies targeting epitopes across the LRRK2 protein. In the present paper, we report optimized protocols and results for ten monoclonal antibodies for immunoblotting, immunohistochemistry, immunoprecipitation and kinase activity assays, in rat, mouse and human brain tissue. Several efficacious antibodies were identified, but results demonstrate that the mouse monoclonal N241A/34 is suitable for most applications, with the best overall rabbit monoclonal antibody being c41-2. These antibodies produced a dominant band of the expected size via immunoblotting and a lack of labelling in tissue derived from LRRK2-knockout animals under optimized conditions. A significant proportion of LRRK2 protein localizes to insoluble fractions and no evidence of truncated LRRK2 protein was detected in any fraction from rodent or human tissues. An assay was developed for the robust detection of LRRK2 kinase activity directly from frozen mouse and human brain tissue, but precipitous declines in activity were observed that corresponded to increasing post-mortem intervals and processing times. Finally, we demonstrate the highest levels of brain-localized LRRK2 in the striatum, but note differential expression patterns between rat and mouse in both striatum and cortex. Anti-LRRK2 monoclonal antibodies that are unlimited in availability together with the proposed standardized protocols should aid in the definition of LRRK2 function in both health and disease.",
keywords = "Immunohistochemistry, Kinase assay, Leucine-rich repeat kinase 2 (LRRK2), Parkinson's disease",
author = "Paul Davies and Hinkle, {Kelly M.} and Sukar, {Nour N.} and Bryan Sepulveda and Roxana Mesias and Geidy Serrano and Alessi, {Dario R.} and Beach, {Thomas G.} and Benson, {Deanna L.} and White, {Charles L.} and Cowell, {Rita M.} and Das, {Sonal S.} and West, {Andrew B.} and Melros, {Heather L.}",
year = "2013",
month = "7",
day = "1",
doi = "10.1042/BJ20121742",
language = "English (US)",
volume = "453",
pages = "101--113",
journal = "Biochemical Journal",
issn = "0264-6021",
publisher = "Portland Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies

AU - Davies, Paul

AU - Hinkle, Kelly M.

AU - Sukar, Nour N.

AU - Sepulveda, Bryan

AU - Mesias, Roxana

AU - Serrano, Geidy

AU - Alessi, Dario R.

AU - Beach, Thomas G.

AU - Benson, Deanna L.

AU - White, Charles L.

AU - Cowell, Rita M.

AU - Das, Sonal S.

AU - West, Andrew B.

AU - Melros, Heather L.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Missense mutations in LRRK2 (leucine-rich repeat kinase 2) are a major cause of PD (Parkinson's disease). Several antibodies against LRRK2 have been developed, but results using these polyclonal antibodies have varied widely leading to conflicting conclusions. To address this challenge, the Michael J. Fox Foundation for Parkinson's Research generated a number of monoclonal antibodies targeting epitopes across the LRRK2 protein. In the present paper, we report optimized protocols and results for ten monoclonal antibodies for immunoblotting, immunohistochemistry, immunoprecipitation and kinase activity assays, in rat, mouse and human brain tissue. Several efficacious antibodies were identified, but results demonstrate that the mouse monoclonal N241A/34 is suitable for most applications, with the best overall rabbit monoclonal antibody being c41-2. These antibodies produced a dominant band of the expected size via immunoblotting and a lack of labelling in tissue derived from LRRK2-knockout animals under optimized conditions. A significant proportion of LRRK2 protein localizes to insoluble fractions and no evidence of truncated LRRK2 protein was detected in any fraction from rodent or human tissues. An assay was developed for the robust detection of LRRK2 kinase activity directly from frozen mouse and human brain tissue, but precipitous declines in activity were observed that corresponded to increasing post-mortem intervals and processing times. Finally, we demonstrate the highest levels of brain-localized LRRK2 in the striatum, but note differential expression patterns between rat and mouse in both striatum and cortex. Anti-LRRK2 monoclonal antibodies that are unlimited in availability together with the proposed standardized protocols should aid in the definition of LRRK2 function in both health and disease.

AB - Missense mutations in LRRK2 (leucine-rich repeat kinase 2) are a major cause of PD (Parkinson's disease). Several antibodies against LRRK2 have been developed, but results using these polyclonal antibodies have varied widely leading to conflicting conclusions. To address this challenge, the Michael J. Fox Foundation for Parkinson's Research generated a number of monoclonal antibodies targeting epitopes across the LRRK2 protein. In the present paper, we report optimized protocols and results for ten monoclonal antibodies for immunoblotting, immunohistochemistry, immunoprecipitation and kinase activity assays, in rat, mouse and human brain tissue. Several efficacious antibodies were identified, but results demonstrate that the mouse monoclonal N241A/34 is suitable for most applications, with the best overall rabbit monoclonal antibody being c41-2. These antibodies produced a dominant band of the expected size via immunoblotting and a lack of labelling in tissue derived from LRRK2-knockout animals under optimized conditions. A significant proportion of LRRK2 protein localizes to insoluble fractions and no evidence of truncated LRRK2 protein was detected in any fraction from rodent or human tissues. An assay was developed for the robust detection of LRRK2 kinase activity directly from frozen mouse and human brain tissue, but precipitous declines in activity were observed that corresponded to increasing post-mortem intervals and processing times. Finally, we demonstrate the highest levels of brain-localized LRRK2 in the striatum, but note differential expression patterns between rat and mouse in both striatum and cortex. Anti-LRRK2 monoclonal antibodies that are unlimited in availability together with the proposed standardized protocols should aid in the definition of LRRK2 function in both health and disease.

KW - Immunohistochemistry

KW - Kinase assay

KW - Leucine-rich repeat kinase 2 (LRRK2)

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84879024830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879024830&partnerID=8YFLogxK

U2 - 10.1042/BJ20121742

DO - 10.1042/BJ20121742

M3 - Article

VL - 453

SP - 101

EP - 113

JO - Biochemical Journal

JF - Biochemical Journal

SN - 0264-6021

IS - 1

ER -